Oct 2, 2017
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has grabbed attention from the analysts, when it experienced a change of 0.98% in Monday’s afternoon trading session to trade at $38.04. A total of 626,205…
seen from Netherlands
seen from Colombia
seen from China
seen from China
seen from United States
seen from Spain
seen from Germany
seen from United States
seen from Malaysia
seen from Germany
seen from China
seen from United States
seen from Australia
seen from Canada
seen from China
seen from China
seen from Malaysia
seen from China
seen from Germany
seen from United States
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has grabbed attention from the analysts, when it experienced a change of 0.98% in Monday’s afternoon trading session to trade at $38.04. A total of 626,205…
Analyst Activity – Leerink Swann Reiterates Market Perform on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Activity – Leerink Swann Reiterates Market Perform on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Ratings For Acadia Pharmaceuticals (NASDAQ:ACAD) Today, Leerink Swann reiterated its Market Perform rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a price target of $29.00. There are 4 hold ratings, 8 buy ratings on the stock. The current consensus rating on Acadia Pharmaceuticals (NASDAQ:ACAD) is Buy (Score: 2.67) with a consensus target price of $40.64 per share, a potential 42.48%…
View On WordPress
Analyst Activity – HC Wainwright Reiterates Buy on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Activity – HC Wainwright Reiterates Buy on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Ratings For Acadia Pharmaceuticals (NASDAQ:ACAD) Today, HC Wainwright reiterated its Buy rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a price target of $60.00. There are 4 hold ratings, 8 buy ratings on the stock. The current consensus rating on Acadia Pharmaceuticals (NASDAQ:ACAD) is Buy (Score: 2.67) with a consensus target price of $40.64 per share, a potential 36.59% upside.…
View On WordPress
Analyst Activity – HC Wainwright Reiterates Buy on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Activity – HC Wainwright Reiterates Buy on Acadia Pharmaceuticals (NASDAQ:ACAD)
Analyst Ratings For Acadia Pharmaceuticals (NASDAQ:ACAD) Today, HC Wainwright reiterated its Buy rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a price target of $60.00. There are 4 hold ratings, 8 buy ratings on the stock. The current consensus rating on Acadia Pharmaceuticals (NASDAQ:ACAD) is Buy (Score: 2.67) with a consensus target price of $40.64 per share, a potential 36.59% upside.…
View On WordPress
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other Events
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other Events
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other EventsItem 8.01 Other Events. On December 20, 2016, ACADIA Pharmaceuticals Inc. announced positive top-line results from its Phase II exploratory study of pimavanserin in patients with Alzheimer’s disease psychosis, or AD Psychosis. In this Phase II exploratory study, referred to as the -019 study, pimavanserin met the primary endpoint…
View On WordPress
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other Events
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other Events
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Other EventsItem 8.01 Other Events. On December 20, 2016, ACADIA Pharmaceuticals Inc. announced positive top-line results from its Phase II exploratory study of pimavanserin in patients with Alzheimer’s disease psychosis, or AD Psychosis. In this Phase II exploratory study, referred to as the -019 study, pimavanserin met the primary endpoint…
View On WordPress
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PJT Partners Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2016 -- PJT
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PJT Partners Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2016 — PJT
NEW YORK, NY–(Marketwired – April 27, 2016) – The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of PJT Partners Inc. (“PJT”) (NYSE: PJT) between November 12, 2015 and March 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of…
View On WordPress
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of G. Willi-Food International Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2016 -- WILC
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of G. Willi-Food International Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2016 — WILC
NEW YORK, NY–(Marketwired – March 11, 2016) – The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of G. Willi-Food International Inc. (“WILC” or the “Company”) (NASDAQ: WILC) between April 30, 2014 and February 18, 2016. You are hereby notified that a securities class action has been commenced in the USDC for…
View On WordPress